TheraJect, Inc. is a preclinical stage biopharmaceutical company committed to the drug delivery including vaccines via a novel, needle-free transdermal technology. TheraJect is focused on enhancing the efficacy of existing vaccines, enabling new vaccines and expanding the global vaccine market. The TheraJect patch consists of an array of dissolvable microneedles that create superficial pathways through the skin's dead barrier layer, allowing transport of macromolecules into the viable epidermis. The array is held in place by a traditional adhesive patch. The microneedles dissolve within minutes in the interstitial fluid, delivering the drug or vaccine. The microneedle components are selected from a broad range of dissolving materials, all of which are either GRAS or have been used in injectibles. The drug or vaccine to be delivered is mixed with the microneedle materials to form a hydrogel, poured into a mould, dried and then cut and assembled with an adhesive patch. This extremely simple, âfill and finishâ like process is eminently scalab
